Prognostic Value of Day 3 Estradiol on In Vitro Fertilization Outcome

Smotrich, David B.; Widra, E.A.; Gindoff, Paul R.; Levy, Michael J.; Hall, Jerry L.; Stillman, Robert J.

doi:10.1097/00006254-199604000-00017

Cited by 69 publications

(90 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concerning biological values, differences were significant only among sub-samples in group 45,X/46,XX but never between 45,X/46,XX subsamples and control women. However, the highest mean E 2 levels did not reach that considered as poor prognostic value (O80 pg/ml) by Smotrich et al at day 2 or 3 of menses (26), which means the tests used in our study were not discriminating enough, or mosaicism had no real impact on ovarian reserve. Parameters with more sensitivity to answer this question may be lacking in our study because of our retrospective study range starting from 1996 to 2006, we had neither antral follicular count nor anti-Mullerian hormone assessments, which now seem to provide more discriminating acuteness in adulthood (27)(28)(29).…”

Section: Discussioncontrasting

confidence: 84%

45,X/46,XX mosaicism below 30% of aneuploidy: clinical implications in adult women from a reproductive medicine unit

Homer

Martelot

Morel

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Turner's syndrome (TS) is well known, but prognosis for 45,X/46,XX mosaicism below 30% of aneuploidy has not been established. We evaluated differences in clinical features and biological parameters between patients with numerical sex chromosome mosaicism diagnosed incidentally and control women. Design: Retrospective observational study of clinical features and biological parameters. Methods: Standard endocrinological and gynecological examination was done and early-follicularphase blood values were collected from the medical records of women aged 21-43, who were referred to our ward from 1996 to 2006 because of infertility and were karyotyped. Seventy-one women with sex chromosome mosaicism (45,X/46,XX) ranging from 4 to 28% were assigned a chromosomally normal woman (46,XX) matched according to age (nZ71). Results: In group 45,X/46,XX, 8% or more of aneuploidy accounted for a smaller height compared to controls (PZ0.01). Body mass index was increased from 6% of aneuploidy (PZ0.02) and was positively correlated to the percentage of 45,X cells (PZ0.0001); menarche occurred earlier from 10% of aneuploidy (PZ0.01) and was inversely correlated to the percentage of 45,X cells (PZ0.045). No difference was found between the groups for FSH, LH, estradiol, inhibin B, and TSH values. Spontaneous abortions were more frequent in case of mosaicism (PZ0.01), and recurrence was positively correlated to the percentage of aneuploidy (PZ0.008). Conclusion: Sex chromosome mosaicism is responsible for clinical changes from 6% of aneuploidy, corresponding to the main phenotypical features of TS.

show abstract

Section: Discussioncontrasting

confidence: 84%

45,X/46,XX mosaicism below 30% of aneuploidy: clinical implications in adult women from a reproductive medicine unit

Homer

Martelot

Morel

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In such patients, an elevated early follicular E2 level predicts a significant increase in cancellation rates and a decrease in pregnancy rates when it is over 70 pg/mL. 88 Low inhibin B levels (<45 pg/mL) may reflect diminished ovarian reserve, 89 but the normal range is very wide, and a poor discriminatory zone has thus far limited its utility as a marker in all but the most severely compromised patients. One of the main disadvantages of the previously mentioned assays is that their secretion varies greatly during the menstrual cycle, and they have to be performed during the second or third day of the cycle.…”

Section: It Is Imperative For the Physician To Appropriately Counsel mentioning

confidence: 99%

Advances and Controversies in Assisted Reproductive Technology

Vela

Luna

Sandler

et al. 2009

Mount Sinai J Medicine

View full text Add to dashboard Cite

As the incidence and awareness of infertility have increased in the last decades, reproductive endocrinologists and scientists have striven to improve the therapeutic options being offered to patients. One of the most advanced and efficient technologies currently being offered is assisted reproductive technology. Among the various techniques that are comprised by assisted reproductive technology, in vitro fertilization is the most widely studied and used, being responsible for approximately 1% of all live births in the United States. As this technology has evolved, many controversies have arisen, and it is the purpose of this article to review what in the authors' opinion are the most current and controversial aspects of the whole process of in vitro fertilization and its related techniques. Mt Sinai J Med 76:506‐520, 2009. © 2009 Mount Sinai School of Medicine

show abstract

“…Various screening tests have been introduced to predict poor ovarian responders before initiation of ovulation induction to tailor the treatment strategy and doses of medication to that patient. Previous ART cycle outcomes, age, antral follicle count, ovarian volume, day 3 FSH, E2, inhibin, anti-Müllerian hormone (AMH), and dynamic ovarian reserve tests are currently used as predictive tests for determining ovarian response to COH [Koshy et al 2013;Muasher et al 1988;Mutlu et al 2013;Oudendijk et al 2012;Smotrich et al 1995;Watt et al 2000]. However, apart from the actual ovarian follicular response to ovarian stimulation itself, none of the predictive tests for ovarian reserve have been found to be sufficiently accurate for predicting the ovarian response.…”

Section: Discussionmentioning

confidence: 99%

Can serum estradiol levels on the fourth day of IVF/ICSI cycle predict outcome in poor responder women?

Kahyaoğlu

Yumusak

Özgü-Erdinç

et al. 2015

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

We aimed to investigate the value of fourth day serum estradiol levels in predicting cycle outcome in poor responders. The medical records of 426 patients with low oocyte yield following controlled ovarian hyperstimulation (COH) treatment for a procedure in our institution's center for ART between 2008 and 2013 were evaluated. Eighty-eight patients exhibiting poor ovarian response (POR) were included in the study. The clinical outcomes of IVF/ICSI were compared based on the basal hormone profile, clinical, and laboratory parameters. Cycle day 4 E2 levels below 110 pg/ml had an odds ratio of 6.05 (95% CI 2.33-15.7; p50.001) for embryo transfer. The early follicular response to ovarian stimulation can be anticipated with the cycle day 4 estradiol levels during COH. When a low day 4 serum estradiol level is encountered, abandoning the current COH and proceeding with agents that increase ovarian response to ovarian stimulation before the next treatment cycle can be a realistic approach.

show abstract

Prognostic Value of Day 3 Estradiol on In Vitro Fertilization Outcome

Cited by 69 publications

References 0 publications

45,X/46,XX mosaicism below 30% of aneuploidy: clinical implications in adult women from a reproductive medicine unit

45,X/46,XX mosaicism below 30% of aneuploidy: clinical implications in adult women from a reproductive medicine unit

Advances and Controversies in Assisted Reproductive Technology

Can serum estradiol levels on the fourth day of IVF/ICSI cycle predict outcome in poor responder women?

Contact Info

Product

Resources

About